Oryzon Genomics Sa Stock Net Income
| ORYZF Stock | USD 3.60 0.24 7.14% |
As of the 3rd of February, Oryzon Genomics holds the Risk Adjusted Performance of 0.006, variance of 1.52, and Coefficient Of Variation of 37419.7. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oryzon Genomics, as well as the relationship between them. Please check Oryzon Genomics SA risk adjusted performance, variance, as well as the relationship between the Variance and kurtosis to decide if Oryzon Genomics SA is priced some-what accurately, providing market reflects its current price of 3.6 per share. Given that Oryzon Genomics has variance of 1.52, we recommend you to check out Oryzon Genomics SA's recent market performance to make sure the company can sustain itself at a future point.
Oryzon Genomics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Oryzon Genomics' valuation are provided below:Oryzon Genomics SA does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Oryzon |
Oryzon Genomics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Oryzon Genomics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Oryzon Genomics.
| 11/05/2025 |
| 02/03/2026 |
If you would invest 0.00 in Oryzon Genomics on November 5, 2025 and sell it all today you would earn a total of 0.00 from holding Oryzon Genomics SA or generate 0.0% return on investment in Oryzon Genomics over 90 days. Oryzon Genomics is related to or competes with Silence Therapeutics, Genfit SA, Transgene, Hansa Biopharma, JW (Cayman), and NervGen Pharma. Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetic... More
Oryzon Genomics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Oryzon Genomics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Oryzon Genomics SA upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 7.14 |
Oryzon Genomics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oryzon Genomics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Oryzon Genomics' standard deviation. In reality, there are many statistical measures that can use Oryzon Genomics historical prices to predict the future Oryzon Genomics' volatility.| Risk Adjusted Performance | 0.006 | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.08) | |||
| Treynor Ratio | (0.05) |
Oryzon Genomics February 3, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.006 | |||
| Market Risk Adjusted Performance | (0.04) | |||
| Mean Deviation | 0.2164 | |||
| Coefficient Of Variation | 37419.7 | |||
| Standard Deviation | 1.23 | |||
| Variance | 1.52 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.08) | |||
| Treynor Ratio | (0.05) | |||
| Maximum Drawdown | 7.14 | |||
| Skewness | 0.2645 | |||
| Kurtosis | 32.53 |
Oryzon Genomics SA Backtested Returns
At this point, Oryzon Genomics is somewhat reliable. Oryzon Genomics SA maintains Sharpe Ratio (i.e., Efficiency) of close to zero, which implies the firm had a close to zero % return per unit of risk over the last 3 months. We have found twenty technical indicators for Oryzon Genomics SA, which you can use to evaluate the volatility of the company. Please check Oryzon Genomics' Coefficient Of Variation of 37419.7, risk adjusted performance of 0.006, and Variance of 1.52 to confirm if the risk estimate we provide is consistent with the expected return of 0.0035%. The company holds a Beta of 0.13, which implies not very significant fluctuations relative to the market. As returns on the market increase, Oryzon Genomics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Oryzon Genomics is expected to be smaller as well. Oryzon Genomics SA right now holds a risk of 1.27%. Please check Oryzon Genomics SA variance, as well as the relationship between the kurtosis and price action indicator , to decide if Oryzon Genomics SA will be following its historical price patterns.
Auto-correlation | -0.28 |
Weak reverse predictability
Oryzon Genomics SA has weak reverse predictability. Overlapping area represents the amount of predictability between Oryzon Genomics time series from 5th of November 2025 to 20th of December 2025 and 20th of December 2025 to 3rd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Oryzon Genomics SA price movement. The serial correlation of -0.28 indicates that nearly 28.0% of current Oryzon Genomics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.28 | |
| Spearman Rank Test | -0.2 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Oryzon Genomics SA reported net income of (4.69 Million). This is 101.37% lower than that of the Healthcare sector and 106.69% lower than that of the Biotechnology industry. The net income for all United States stocks is 100.82% higher than that of the company.
Oryzon Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oryzon Genomics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Oryzon Genomics could also be used in its relative valuation, which is a method of valuing Oryzon Genomics by comparing valuation metrics of similar companies.Oryzon Genomics is currently under evaluation in net income category among its peers.
Oryzon Fundamentals
| Return On Equity | -0.0685 | |||
| Return On Asset | -0.0419 | |||
| Profit Margin | (0.33) % | |||
| Operating Margin | (0.72) % | |||
| Current Valuation | 106.94 M | |||
| Shares Outstanding | 55.26 M | |||
| Shares Owned By Insiders | 18.04 % | |||
| Shares Owned By Institutions | 0.72 % | |||
| Price To Book | 1.77 X | |||
| Price To Sales | 13.40 X | |||
| Gross Profit | 9.87 M | |||
| EBITDA | (6.58 M) | |||
| Net Income | (4.69 M) | |||
| Cash And Equivalents | 28.72 M | |||
| Cash Per Share | 0.54 X | |||
| Total Debt | 10.35 M | |||
| Debt To Equity | 0.25 % | |||
| Current Ratio | 3.76 X | |||
| Book Value Per Share | 1.35 X | |||
| Cash Flow From Operations | (3.63 M) | |||
| Earnings Per Share | (0.09) X | |||
| Number Of Employees | 43 | |||
| Beta | 1.02 | |||
| Market Capitalization | 143.68 M | |||
| Total Asset | 95.38 M | |||
| Z Score | 7.8 | |||
| Net Asset | 95.38 M |
About Oryzon Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oryzon Genomics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oryzon Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oryzon Genomics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Oryzon Pink Sheet
Oryzon Genomics financial ratios help investors to determine whether Oryzon Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oryzon with respect to the benefits of owning Oryzon Genomics security.